2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	diagnostic usage	1	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	therapeutic application	2	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	ongoing research	3	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	unassigned	-	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	diagnostic usage	1	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	therapeutic application	2	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	ongoing research	3	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	unassigned	-	
2.4.1.219	Gaucher Disease	https://pubmed.ncbi.nlm.nih.gov/33361282/	Human glucocerebrosidase mediates formation of xylosyl-cholesterol by ?-xylosidase and transxylosidase reactions.	causal interaction	4	
2.4.1.219	Gaucher Disease	https://pubmed.ncbi.nlm.nih.gov/33361282/	Human glucocerebrosidase mediates formation of xylosyl-cholesterol by ?-xylosidase and transxylosidase reactions.	unassigned	-